Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma
Bookmark1. Patients in the camrelizumab-rivoceranib group reported significantly greater...
Read MoreOct 12, 2023
Bookmark1. Patients in the camrelizumab-rivoceranib group reported significantly greater...
Read MoreOct 12, 2023
Bookmark1. Patients with centrally located breast cancer (CLBC) had higher breast cancer-specific...
Read MoreOct 11, 2023
Bookmark1. Recurrence-free survival was significantly different between the adjuvant everolimus...
Read MoreOct 10, 2023
Bookmark1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort...
Read MoreOct 10, 2023
Bookmark1. The GI-Genius neural network system did not improve the rate of detecting advanced...
Read MoreOct 8, 2023
Bookmark1. In this case-control study, younger age of onset of non-alcoholic fatty liver disease...
Read MoreOct 3, 2023
Bookmark1. The hazard ratio of skeletal-related events in patients treated with radiation compared...
Read MoreOct 3, 2023
Bookmark1. 5-year distant disease-free survival was comparable between both groups. 2. 5-year...
Read MoreSep 27, 2023
Bookmark1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with...
Read MoreSep 27, 2023
Bookmark1. This phase 2 randomized clinical trial found that patients with metastatic colorectal...
Read MoreSep 22, 2023
Bookmark1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in...
Read MoreSep 19, 2023
Bookmark1. 37% of study patients had an objective response to treatment with atezolizumab. 2....
Read MoreSep 19, 2023
Bookmark1. The objective response rate was 29.8% (1% complete response, 66% partial response) with...
Read MoreSep 13, 2023
Bookmark1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88...
Read MoreSep 2, 2023
Bookmark1. This post-hoc analysis of the AMATERASU randomized clinical trial found that, for...
Read MoreAug 31, 2023
Bookmark1. In a cross-sectional study, adolescent survivors of childhood cancers were more...
Read MoreAug 31, 2023
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read MoreAug 25, 2023
Bookmark1. The risk of mortality from solid cancer, lagged by 10 years, is estimated to be...
Read MoreAug 22, 2023
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read MoreAug 22, 2023
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read More